Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Vroom’s Insiders Make It a Long-Term Buy

By Will Ashworth, InvestorPlace Contributor

While Vroom stock has catapulted since its IPO, there's still room for growth because of the big backers supporting the cause.

Here are 2 Great Companies to Invest in on Crowdfunder

By Will Ashworth, InvestorPlace Contributor

One of the top equity crowdfunding portals is Crowdfunder. Here are two companies to invest in from its current fundraising campaigns.

Does Walgreens Stock Need a Positive Earnings Surprise to Move Higher?

By Will Ashworth, InvestorPlace Contributor

Walgreens stock has been uninspiring heading into earnings season. You shouldn't expect too much from WBA.

Did Warren Buffett Contribute to Occidental Pete’s Demise?

By Will Ashworth, InvestorPlace Contributor

For those unfamiliar with Buffett’s relationship with Occidental, his company lent OXY $10 billion last August to help it acquire Anadarko, beating out Chevron (NYSE:CVX) in the process. In hindsight, Chevron’s CEO has got to be ecstatic it lost the fight.

Inovio Pharmaceuticals Comes Up Short in Phase 1

By Will Ashworth, InvestorPlace Contributor

The competition for a Covid-19 vaccine is intense. Inovio needs to provide investors with more information to give INO stock a chance at long-term upside.

Load More